Publications by authors named "Pamela Ramseier"
Introduction: Siponimod, a potent and selective sphingosine-1-phosphate (S1P) agonist, is the only therapeutic agent that has shown efficacy against disability progression, decline in cognitive processing speed, total brain volume loss, gray matter atrophy and signs of demyelination in patients with secondary progressive multiple sclerosis (SPMS). Although the pathophysiology of progression in SPMS and primary progressive MS (PPMS) is thought to be similar, fingolimod, the prototype S1P agonist, failed to show efficacy against disability progression in PPMS. Differentiating siponimod from fingolimod at the level of their central effects is believed to be the key to a better understanding of the underlying characteristics that could make siponimod uniquely efficacious in progressive MS (PMS).
View Article and Find Full Text PDFArticle Synopsis
- Siponimod is an oral medication approved for treating multiple sclerosis, showing promise in promoting remyelination and reducing inflammation in various mouse models of demyelination.
- In experiments, siponimod treatment led to improved remyelination in the cuprizone model and better visual function in the EAEON model, following a bell-shaped dose-response curve where moderate doses were more effective than high ones.
- The study highlights siponimod's immunomodulatory properties and its potential to shift microglial differentiation towards supporting myelin repair, suggesting that optimal dosing is crucial for maximizing its therapeutic effects.